Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERME (Enzym-Rich Malt Extract) is a proprietary, barley-derived nutraceutical ingredient developed by Ateria Health. It comprises a natural mixture of plant-derived enzymes, specifically amylases and glucanases, which facilitate the breakdown of starch and plant materials in the digestive tract. By optimizing carbohydrate metabolism, ERME prevents mal-fermentation in the gut, thereby supporting a healthy microbiome—a process the developer refers to as 'anabiomic.' It is the primary active component in the JUVIA Digestive Balance Formula, which is marketed to improve gut health and alleviate symptoms associated with Irritable Bowel Syndrome (IBS). Research also suggests potential applications in other conditions such as asthma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ERME.